Entero-Logo-Options-FINAL.png
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
10 sept. 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Canadian Post Second
Canadian Post Secondary Institutions Fall Short on Gluten-Free Accommodations
27 août 2024 15h56 HE | Celiac Canada
Toronto, ON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A recent survey conducted by Celiac Canada reveals that Canadian universities and colleges are not providing adequate gluten-free accommodations on...
Barinthus Biotherapeutics Pipeline
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
08 août 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Entero-Logo-Options-FINAL.png
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
31 juil. 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
VMR Logo.png
Gluten Free Products Market Surges to USD 8.73 Billion by 2031, Propelled by 7.20% CAGR - Verified Market Research®
18 juil. 2024 10h00 HE | Verified Market Research
Lewes, Delaware, July 18, 2024 (GLOBE NEWSWIRE) -- The Global Gluten Free Products Market Size is projected to grow at a CAGR of 7.20% from 2024 to 2031, according to a new report published by...
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Entero-Logo-Options-FINAL.png
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 mai 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) --  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
Entero-Logo-Options-FINAL.png
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20 mai 2024 07h00 HE | Entero Therapeutics, Inc.
BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Entero-Logo-Options-FINAL.png
First Wave BioPharma Changes Name to Entero Therapeutics
16 mai 2024 07h00 HE | Entero Therapeutics, Inc.
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 ...
barinthuslogo.jpg
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 mai 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments